subject: Advantage of not reducing the total European outsourcing 55% share of the world - outsourcing, Europe - Pharmaceutical Industry [print this page] Advantage of not reducing the total European outsourcing 55% share of the world - outsourcing, Europe - Pharmaceutical Industry
Despite the current global economic recession, the industry environment is difficult, but in Europe Preparation Outsourcing service providers who are enjoying substantial benefits. Analyze and summarize their successful experiences are worth our Pharmaceutical Industry Reference
Held this year in Frankfurt, CPhI exhibition, most notably the European outsourcing services, thus, people have a comprehensive understanding of the industry. According to data provided PharmSource Europe Preparation Outsourcing services market was 57.5 billion U.S. dollars, accounting for the global outsourcing market, 55% of the preparation.
Although PharmSource outsourcing database contains more than 160 preparations leading outsourcing companies, but impressive is the preparation outsourcing service provider of most of the top 10 were from Europe (see table). In the current global economic downturn, the industry environment more difficult circumstances, preparation outsourcing service providers in Europe's success is worth learning from.
Disadvantage Poor state of the market environment, the agents of European outsourcing service providers face many obstacles, including:
sales environment: New Drugs Prices and consumer acceptance by the European governments strictly controlled, in this case, the system Pharmaceutical companies Industry to bear the pressure to reduce costs as much as possible, that from the profits of European outsourcing service providers can be seen.
exchange: low among dollar and the euro exchange rate, so that European and American counterparts outsourcing service providers compete in an increasingly unfavorable position.
overcapacity: the issue of labor law, companies shut down redundant production base will be faced with high costs, which makes outsourcing service providers can only be the same as the large pharmaceutical companies to sell excess capacity. As another alternative way, the European Outsourcing Association to low cost production base to sell a number of management organizations.
regional bias: Although the growth in the EU to maintain the success of outsourcing services to enterprises, but Europe is still facing regional bias. For example, the French pharmaceutical companies tend to outsource service providers in France, and the same, firms tend to Spain Spain outsourcing service provider.
Success factors Despite the adverse factors mentioned above, but the large European outsourcing service providers or success. Success factors of these enterprises are:
with major pharmaceutical companies to establish a good connection. Europe's largest outsourcing service provider with global pharmaceutical giant has established long-term relationship, which would reduce regional bias. In the outsourcing service provider from the hands of large pharmaceutical companies get their redundancy when production base, we gained many years of production left over for the major pharmaceutical products, contracts, and thus with these large pharmaceutical companies have countless ties .
comprehensive regional network. Vast majority of outsourcing service providers in several countries have set up manufacturing base, which is considered by the regional companies in these countries to find potential customers. For example, an outsourcing service provider, says that since 2007, the acquisition of a non-gastrointestinal tract in the administration of the French production base, the French pharmaceutical company to conduct business more willing to cooperate with them, even if the rest of Europe are better suited for those French pharmaceutical companies outsourcing service provider.
strong specialized capacity. Many outsourcing service providers in addition to capacity with conventional dosage forms but also have the need for separation of the mixture of the special processing capacity.
import barriers. As the GMP regulations are different from countries outside Europe imported drugs face greater obstacles, allowing a number of outsourcing service providers in Europe benefit from the other, local production of clinical supplies more favorable.
